\
&
Contact us
\
&
Contact us
This was 1 month ago
LocationOnline
ProgrammesThe Horizon Europe Health (Cluster 1) Info Day is organised by the European Commission to provide (prospective) applicants the opportunity to familiarise with the 2026 topics of the forthcoming work programme 2026 - 2027 and raise questions.
Please note that the Commission encourages participants to watch the pre-recorded presentations ahead of the event. These pre-recorded presentations will appear on the Commission website some time before the event. You can send your questions in advance via Sli.do by using #HORIZON.
More information and the detailed programme coming soon on the Commission website.
The Commission Info Day will be preceded by a Brokerage event on 26 - 30 January 2026, organised by the Horizon Europe Cluster 1 National Contact Points through HNN3.0 initiative. This will complement the Info Day with an offer of matchmaking opportunities to prospective applicants to support the building of consortia.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
